ARG-007 Reduces Effects of TBI in Preclinical Study
Filed with ASX · · 8 pages · English
Argenica Therapeutics Ltd on 6ix
Story so far
Earlier from Argenica Therapeutics
- DSMB Confirms Safety of First Patients Dosed
- Argenica Successfully Completes $12.0m Placement
- Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
- First Patient Dosed in Phase 2 Stroke Trial of ARG-007
- FDA Grants Rare Pediatric Disease Designation For HIE
Later from Argenica Therapeutics
- Appendix 4E & Annual Report to 30 June 2024
- Positive Results in Key IND Enabling Studies
- FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
- Quarterly Activities/Appendix 4C Cash Flow Report - updated
- $2.76m R&D Tax Incentive Cash Rebate Received for FY24
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics